• DRAMP ID

    • DRAMP18058
    • Name

    • Daptomycin(Cubicin, LY-164032)
    • Sequence

    • decanoyl-Trp-Asn-Asp-Thr-Gly-Orn-Asp-D-Ala-Asp-Gly-D-Ser-Glu(3R-Me)-Asp(Ph(2-NH2))
    • Description

    • Daptomycin is a cyclic lipopeptide antibiotic used to treat complicated skin and skin structure infections by susceptible Gram-positive bacteria and bacteremia due to Staphylococcus aureus.
    • Activity

    • Antibacterial
    • Target Organism

      • No MICs found on DRAMP database
    • Reference

      • Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia. (PMID: 29508663)
    • Medical use

    • Treatment of complicated skin and skin structure infections (cSSSI), Staphylococcus aureus bloodstream infections (bacteremia)
    • Company

    • Cubist Pharmaceuticals LLC (Merck & Co.)
    • Stage of Development

    • In market
    • Comments

    • Studies have suggested a direct inhibition of cell membrane/cell wall constituent biosynthesis, including peptidoglycan, uridine diphosphate-N-acid, acetyl-L-alanine, and lipoteichoic acid (LTA).